Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

67.96 +1.36 (+2.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,478,994
Open 67.75
Bid (Size) 66.60 (3)
Ask (Size) 67.91 (3)
Prev. Close 66.60
Today's Range 67.59 - 68.38
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data. 
Via Benzinga
Exposures Product Safety
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool

Performance

YTD
+3.16%
+3.16%
1 Month
+2.00%
+2.00%
3 Month
-12.24%
-12.24%
6 Month
-14.15%
-14.15%
1 Year
+1.22%
+1.22%

More News

Read More
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
From AstraZeneca
Via Business Wire
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
Via Benzinga
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma
Via Benzinga
Exposures Product Safety
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 – AZN
From Faruqi & Faruqi LLP
Via GlobeNewswire
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
From AstraZeneca
Via Business Wire
3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices
Via The Motley Fool
AZN DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 21, 2025
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AZN DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 21, 2025
Via TheNewswire.com
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action
From Robbins LLP
Via GlobeNewswire
AZN Deadline to Lead in Securities Fraud Lawsuit is February 21, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
Topics Fraud Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AZN Deadline to Lead in Securities Fraud Lawsuit is February 21, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Topics Fraud Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
Deadline to Lead in Securities Fraud Lawsuit Against AstraZeneca PLC (AZN) is February 21, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Topics Fraud Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Deadline to Lead in Securities Fraud Lawsuit Against AstraZeneca PLC (AZN) is February 21, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
Topics Fraud Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against AstraZeneca PLC (AZN) - Deadline is February 21, 2025
Via TheNewswire.com
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against AstraZeneca PLC (AZN) - Deadline is February 21, 2025
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.